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Interferon (IFN)-c was originally characterized as a pro-inﬂammatory cytokine with T helper
type 1-inducing activity, but subsequent work has demonstrated that mice deﬁcient in IFN-c
or IFN-c receptor show exacerbated inﬂammatory responses and accelerated allograft rejec-
tion, suggesting that IFN-c also has important immunoregulatory functions. Here, we
demonstrate that ex vivo IFN-c conditioning of CD4 T cells driven by allogeneic immature
dendritic cells (DC) results in the emergence of a Foxp3
1 regulatory T-cell (Treg)- dominant
population that can prevent allograft rejection. The development of this population involves
conversion of non-Treg precursors, preferential induction of activation-induced cell death
within the non-Treg population and suppression of Th2 and Th17 responses. The suppressive
activity of IFN-c is dependent on the transcription factor signal transducer and activator
of transcription 1 and is mediated by induced nitric oxide. These data indicate not only how
IFN-c could be used to shape beneﬁcial immune responses ex vivo for possible cell therapy but
also provide some mechanistic insights that may be relevant to exacerbated inﬂammatory
responses noted in several autoimmune and transplant models with IFN-c deﬁciency.
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Introduction
The role of interferon (IFN)-g in cellular immunity is somewhat
paradoxical in that, although it is usually considered to be
a pro-inﬂammatory effector cytokine, increasing evidence
suggests that it plays a non-redundant immunoregulatory
role. For example, experimental autoimmune encephalomyelitis
(EAE) and collagen-induced arthritis (CIA) have been histori-
cally associated with IFN-g-producing Th1-dominant
responses [1], but mice deﬁcient in IFN-g or IFN-g receptor
develop EAE at an accelerated rate [2–4] and, similarly,
deﬁciency in IFN-g or IFN-g receptor leads to more severe
CIA and the development of CIA in otherwise non-susceptible
strains [5–7]. IFN-g can also have immunomodulatory effects
on antigen-presenting cells and a recent report has
demonstrated that adoptive transfer of IFN-g-stimulated
monocyte-derived cells promotes the resolution of experimental
colitis and is associated with an enrichment of CD25
1 Foxp3
1
T cells [8].
A paradoxical role for IFN-g is also seen in organ transplanta-
tion [9–11]. Allograft rejection is a process frequently associated
with a dominant Th1 IFN-g response whereas the absence of
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13]. However, IFN-g appears not to be essential for acute cellular
rejection as both IFN-g-deﬁcient and wild-type mice reject cardiac
allografts with similar kinetics [14, 15] and at least one study has
demonstrated that IFN-g
/ recipients reject skin allografts more
rapidly than their wild-type littermates [9]. In fact, IFN-g may be
required for successful engraftment [9, 16, 17].
Although the classical view of IFN-g is that it favors Th1 cell
development [18, 19], IFN-g also has regulatory functions. For
example, IFN-g can inhibit the proliferation of IL-4-producing Th2
cells [20] and suppress the development of Th17 effector cells
now known to play an important role in many autoimmune
models [21, 22]. In addition, IFN-g also plays an important role in
maintenance of T-cell homeostasis by inducing apoptosis-depen-
dent activation-induced cell death (AICD) to limit T-cell expan-
sion following antigen encounter [23–28]. In the context of
adaptive regulation, we have recently shown that IFN-g is
produced rapidly and transiently by alloantigen-reactive Treg
following reactivation and that this is required for their functional
activity in vivo [29]. IFN-g can induce indoleamine 2,3-dioxy-
genase in several cell types and this enzyme has been shown to
play an important role in limiting T-cell responses in vivo [30–32].
In this study, we demonstrate that ex vivo exposure of CD4
1
T cells to allogeneic bone marrow-derived dendritic cells (DC) in
the presence of IFN-g results in a Treg population that prevents
allograft rejection without further manipulation. The data indi-
cate that IFN-g shifts the balance of the T-cell population in favor
of an enhanced proportion of Foxp3
1 Treg by selectively
enhancing cell death in the non-Treg population and by
promoting direct conversion of non-Treg precursors. Experiments
using DC from IFN-g receptor-deﬁcient mice demonstrate that
this does not depend on a DC response to IFN-g but that T-cell
signalling through the signal transducer and activator of tran-
scription (STAT)1 pathway is essential for the emergence of a
dominant Treg response. Signiﬁcantly, inhibition of nitric oxide
synthase (NOS) abolishes the emergence of the dominant Treg
response and provision of a nitric oxide (NO) donor in the
absence of IFN-g replicates the IFN-g effect, clearly indicating an
important role for NO in this process. Overall, the data highlight a
novel role of IFN-g in the regulation of T-cell homeostasis and
suggest additional possibilities for cell-based therapy in trans-
plantation and autoimmunity.
Results
IFN-c promotes the enrichment of functional
Foxp3
1 Treg
The counter-regulation of Th2 and Th17 responses mediated
by IFN-g, together with previous observations from this labora-
tory indicating that Treg generation in vivo is impaired
in the absence of IFN-g [29], prompted us to ask whether this
cytokine could be used to drive the emergence of alloreactive
regulatory T cells ex vivo. CBA.Ca (CBA) CD4
1 T cells were
stimulated by GM-CSF/TGF-b-conditioned irradiated C57BL/10
(B10) bone marrow-derived DC (BM DC) in the presence of
exogenous IFN-g for 7 days, restimulated under the same
conditions and harvested 7 days later for phenotypic and
functional analysis (Fig. 1A). Under neutral conditions, the
proportion of Foxp3
1 cells remains similar to that in the input
CD4
1 population (5–10%), but the presence of IFN-g results
in a dose-dependent increase in the proportion of Foxp3
1 cells
(Fig. 1B). Replicate experiments (n55) have indicated that the
optimal concentration of IFN-g in this system is 5ng/mL, which
results on average in a ﬁvefold increase in the proportion of
Foxp3
1 cells (po0.05). Unless stated otherwise, this concentra-
tion was used throughout all subsequent experiments. During
development of this protocol, it became clear that, although an
increase in the proportion of Foxp3
1 cells could be seen as early
as day 7, this was rather variable and generally quite low.
However, at day 14, this variability was much less marked and, as
shown in representative FACS plots from a single culture assayed
at days 7 and 14, the proportion of Foxp3
1 cells was signiﬁcantly
greater than at day 7 (Fig. 1C). Therefore, a standardized
stimulation and restimulation approach was used in all experi-
ments with cell harvest at day 14.
To determine whether these IFN-g-conditioned CD4
1
T cells can regulate alloreactive T-cell responses in vivo,
naive CBA CD4
1 T cells were co-cultured with GM-CSF/TGF-b-
differentiated B10 BM DC in the presence of 5ng/mL IFN-g,
harvested on day 14 and then adoptively transferred (210
5)
into CBA-Rag
/ mice with CD25
CD4
1 cells from naive
syngeneic mice as an effector population the day before
transplantation of a B10 skin graft (Fig. 1D). Reconstitution
with CD25
CD4
1 cells alone resulted in acute rejection [median
survival time (MST) 22 days], but cotransfer of IFN-g-conditioned
cells prevented rejection, with all grafts surviving beyond
100 days (po0.01). This effect was alloantigen speciﬁc in
that additional cohorts of mice reconstituted with CD25
CD4
1
cells and IFN-g-conditioned cells driven by B10 BM DC rejected
third-party B10.S (H2
s) skin grafts at a rate not signiﬁcantly
different from those reconstituted with CD25
CD4
1 cells alone
(MST 17.5 days versus 14 days, p50.13; not shown). Impor-
tantly, CD4
1 T cells driven by GM-CSF/TGF-b B10 BM DC in the
absence of IFN-g were unable to regulate rejection in that all B10
skin allografts were rejected acutely (MST519 days, n54,
p40.05; Fig. 1D).
Enrichment of Foxp3
1 cells involves proliferation and
conversion of Foxp3
– precursors
The emergence of an increased proportion of Foxp3
1 regulatory
cells in this system could be explained by apoptosis of responding
non-Treg cells, expansion of endogenous Foxp3
1 cells, or
conversion of non-Treg precursors since total CD4
1 cells
from naive mice were used as the input population in these
experiments. To look for evidence of Treg proliferation in
this system, CBA CD4
1CD25
 input cells were CFSE labeled
and driven with B.10 GM-CSF/TGF-b-conditioned BM DC in
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these cultures contained virtually no Foxp3
1 cells (analysis at
day 0 not possible due to high CFSE ﬂuorescence intensity
immediately after labeling). By day 14, there was a marked
increase in the proportion of Foxp3
1 cells and, importantly,
virtually all of these were CFSE dull or negative, conﬁrming
a close correlation between Foxp3 enrichment and proliferation.
Furthermore, this was dependent on endogenous IL-2 as
shown by the fact that addition of neutralizing anti-IL-2 anti-
body practically abolished the enrichment of Foxp3
1 cells (Fig.
2B). Since it is not possible to determine whether the enrichment
shown in Fig. 2A is due to direct conversion of Foxp3
– cells
or expansion of a small starting population of Foxp3
1 cells
contained in the sorted CD25
 input population, we
took advantage of C57BL/6 (B6) Foxp3-GFP reporter mice [33]
which allowed us to isolate GFP
/Foxp3
 cells by ﬂow sorting.
As shown in Fig. 2C, this input (day 0) population was essentially
devoid of Foxp3
1 cells, but stimulation with DBA/2 (H2
d)
GM-CSF/TGF-b-conditioned BM DC in the presence of 5ng/mL
IFN-g resulted in signiﬁcant conversion such that 17% of
the cells became Foxp3
1. The inﬂuence of IFN-g on conversion
is emphasized by the fact that when the input population
was driven by GM-CSF/TGF-b-conditioned BM DC with-
out exogenous IFN-g but in the presence of 10mg/mL anti-IFN-g
Figure 1. Alloreactive Foxp3
1 T cells emerge in the presence of exogenous IFN-g. (A) Puriﬁed naive CBA CD4
1 T cells were co-cultured with B10 GM-
CSF/TGF-b-differentiated BM DC without exogenous cytokine (neutral conditions) or in the presence of IFN-g (5ng/mL), restimulated under the
same conditions on day 7 and harvested on day 14 for phenotypic and functional analysis. (B) Harvested populations were stained for TCR-b and
Foxp3. Dot plots show representative data at 5ng/mL IFN-g, and the right-hand histogram shows IFN-g dose–response data (means1SD of three
independent experiments). (C) A single culture of CD4
1 T cells driven by B10 GM-CSF/TGF-b-differentiated BM DC in the presence of IFN-g was
assayed for Foxp3 expression on day 7 after a single round of stimulation and on day 14 after restimulation on day 7. (D) Adoptive transfer protocol.
All CBA-Rag
/ mice were reconstituted with 110
5 CD25
CD4
1 cells from naive CBA mice as an effector population with or without ex vivo
conditioned CD4 T cells (Tcon). The reconstituted mice then received a B10 skin graft the following day. Mice reconstituted with 10
5 CD25
CD4
1
cells alone acutely rejected B10 skin grafts (J; MST522 days, n54). Co-transfer of 210
5 CD4 T cells conditioned with IFN-g prevented rejection
of B10 skin grafts (&; MST4100 days, n54; po0.05, & versus J), whereas cotransfer of 210
5 CD4 T cells conditioned without IFN-g did not
prevent rejection (m; MST519 days, n54; p40.05, m versus J). Data are representative of three independent experiments with similar group sizes.
Eur. J. Immunol. 2008. 38: 2512–2527 Gang Feng et al. 2514
& 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euantibody to neutralize endogenous cytokine, conversion
was reduced by tenfold. Overall, these data show that the
enrichment of Foxp3
1 cells in the IFN-g protocol involves
IL-2-dependent Treg proliferation and direct conversion of
Foxp3
– precursors.
IFN-c induces cell death in alloreactive Foxp3
– T cells
Although the IFN-g conditioning protocol described increases the
proportion of Foxp3
1 cells and can convert non-Treg precursors
to Foxp3
1 cells, there is no increase in the absolute number of
Foxp3
1 cells recovered at day 14 (55.3715.510
3 versus
38.7718.610
3 in the absence or presence of 5ng/mL IFN-g,
p40.05; not shown). In addition, the presence of IFN-g
signiﬁcantly reduces the overall number of cells recovered by
2–5-fold. Given that IFN-g contributes to T-cell homeostasis
in vivo through inhibition of proliferation and/or by increasing
AICD [23–25, 28], a simple additional explanation for the
increased proportion of Foxp3
1 cells might be selective elimina-
tion of Foxp3
– cells and, indeed, preliminary results showed a
clear correlation between proliferation and AICD in this
system (not shown). To examine this in more detail, CBA CD4
1
T cells were driven by GM-CSF/TGF-b B10 BM DC, harvested at
various time points and stained for annexin V as marker of
necrotic or apoptotic cell death, washed, ﬁxed and stained for
Foxp3, thus allowing analysis of apoptosis within both Foxp3
1
and Foxp3
– populations. As shown in Fig. 2D, the presence
of IFN-g enhances cell death within the Foxp3
– population at
days 7, 10 and 14, but a more comprehensive analysis at day 14
(the time of cell harvest for functional analysis; Fig. 1) showed
that within the total T-cell population, the addition of IFN-g
resulted in a threefold increase in the proportion of annexin
V
1 cells. Importantly, when cells were analyzed separately
Figure 2. Enrichment of Foxp3
1 cells in the IFN-g protocol involves IL-2-dependent proliferation and conversion from Foxp3
– precursors. (A) CBA
CD25
 cells were ﬂow sorted, CFSE labeled and stimulated with B10 GM-CSF/TGF-b-differentiated BM DC in the presence of IFN-g. Cells were
harvested at day 3 to give a surrogate zero time point (CFSE intensity precluded analysis at day 0) or restimulated under the same conditions on
day 7, harvested on day 14 and stained for Foxp3. (B) Puriﬁed naive CBA CD4
1 T cells were co-cultured with B10 GM-CSF/TGF-b-differentiated BM
DC in the presence of 5ng/mL IFN-g without or with 1mg/mL anti-IL2 antibody (JES6-1A12), restimulated under the same conditions on day 7,
harvested on day 14 and stained for CD25 and Foxp3. (C) FACS-sorted Foxp3/GFP
–CD4
1 T cells from naive Foxp3-GFP knock-in B6 mice were co-
cultured with DBA/2 GM-CSF/TGF-b-differentiated BM DC in the presence of IFN-g (5ng/mL). Cells were restimulated on day 7 under the same
conditions, harvested on day 14, and intracellular Foxp3/GFP expression was examined in the resultant population. In parallel, cells were
stimulated in the absence of IFN-g but the presence of anti-IFN-g antibody. Data are representative of two independent experiments. Numbers in
each dot plot indicate the frequency of cells in the quadrants shown. (D) Puriﬁed naive CBA CD4
1 T cells were cultured with GM-CSF- and TGF-b-
differentiated B10 BM DC (GT-DC) in the absence (left panel) or presence (right panel) of 5ng/mL IFN-g. Cells were harvested on days 3 and 7 (before
restimulation on day 7) and on days 10 and 14 (after restimulation), stained for annexin V, washed, then ﬁxed for analysis of intracellular Foxp3
expression. Numbers in each dot plot indicate the frequency of cells in each quadrant. Data are representative of four independent experiments.
The histogram shows an analysis (means7SD) of four independent experiments gated on Foxp3
– and Foxp3
1 cells; p values were calculated with
the Mann–Whitney test.
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effect on the viability of Foxp3
1 cells (6.372.7 versus 9.574.3%,
absence and presence of IFN-g, respectively) but resulted in a
sixfold increase in cell death within the Foxp3
– population (right
panel, Fig. 2D). Taken together, these data show that the
increased proportion of Foxp3
1 cells and acquisition of regula-
tory function that occurs in this system involves both Treg
conversion and elimination of potential effector cells through
AICD. However, it is important to note that the ability of the
resultant population to prevent allograft rejection (Fig. 1D) is not
due to effector cell elimination during ex vivo conditioning
because in the adoptive transfer model, an adequate effector
population is provided in the form of exogenous naive CD25
 T
cells. Thus, the dominant regulation shown in Fig. 1D appears to
be a direct consequence of Foxp3 induction.
Suppression of IL-6 production by DC contributes to
Treg generation ex vivo
The IFN-g-conditioning system described involves two distinct
phases: conditioning of BM DC with GM-CSF and TGF-b followed
by stimulation of naive CD4
1 T cells with this re-isolated DC
population in the presence of IFN-g. To understand more about
the mechanisms involved in this protocol, we interrogated the
APC and T-cell components of this system independently.
Although mature DC are regarded as key activators of productive
T-cell responses, exposure to immature DC can induce T-cell
unresponsiveness [34]. Phenotypic analysis of DC conditioned
with GM-CSF or GM-CSF1TGF-b conﬁrmed previous observa-
tions [35] that one effect of TGF-b is to maintain these cells in a
relatively immature state as judged by reduced expression of
CD40, CD80 and CD86 (not shown). In view of the fact that GM-
CSF-conditioned DC produce signiﬁcant amounts of IL-6, a
cytokine implicated in the differentiation of Th17 cells and the
negative regulation of Treg [33], we asked whether conditioning
of DC with TGF-b also has an effect on IL-6 expression. BM DC
were conditioned with GM-CSF only or with GM-CSF1TGF-b for
6 days, washed extensively, then stimulated with recombinant
CD40L-Fc to mimic CD40-CD40L interactions without the
confounding inﬂuence of other T-cell–APC interactions, and
analyzed for IL-6 expression by both RT-PCR and ELISA. As
shown in Fig. 3A, the addition of 2ng/mL TGF-b as used in the
DC-conditioning phase reduced both the transcription and
secretion of IL-6 by approximately threefold. Since DC condi-
tioned in the absence of TGF-b do not promote the emergence of
a Foxp3-dominant response in the IFN-g protocol (not shown),
these data indicate that reduced IL-6 production is an important
additional characteristic of the DC required for Treg development
in this system. Furthermore, when GM-CSF-TGF-b-conditioned
DC obtained from IL-6-deﬁcient mice were used to stimulate CBA
CD4
1 T cells in the normal IFN-g protocol, there was a twofold
increase in the proportion of Foxp3
1 cells recovered (Fig. 3B),
again highlighting the reciprocal relationship between IL-6 and
Treg selection in this setting.
The inﬂuence of TGF-b on IL-6 production in the APC popu-
lation used in this conditioning protocol prompted us to examine
the differentiation of Th17 cells, both under neutral conditions
and in the presence of IFN-g. As shown in Fig. 4, naive CBA CD4
1
cells stimulated under neutral conditions with GM-CSF-condi-
tioned DC make dominant Th2 and Th17 responses as judged by
intracellular cytokine staining. However, when the same T-cell
population is stimulated under identical conditions but with DC
conditioned with GM-CSF1TGF-b these responses are reduced
4–6-fold, indicating that one important effect of TGF-b condi-
tioning of the APC population is to skew the T-cell response away
from both Th2 and Th17 pathways. It is interesting to note that,
while the addition of IFN-g has only a modest further effect on
inhibition of Th17 responses, the production of IL-4 is reduced
essentially to background levels. Thus, in addition to an enrich-
ment of Foxp3
1 Treg and the preferential elimination of Foxp3
–
responders, stimulation of naive CD4
1 T cells with TGF-b-
conditioned APC in the presence of IFN-g shapes the ex vivo T-cell
response further by arresting the development of Th2 and Th17
cells, both of which have been implicated in destructive allor-
eactive responses.
Endogenous TGF-b contributes to the emergence of
Treg in this system
In view of the important role of TGF-b in other systems of
Treg generation ex vivo [36–39], we asked whether the impact
of TGF-b in this system is restricted to the effect of
exogenous TGF-b in the APC-conditioning phase or whether
TGF-b from endogenous sources is involved during the T-cell
response itself. As shown in Fig. 5A, BM DC conditioned with
GM-CSF alone express and secrete TGF-b when ligated with
CD40L-Fc in a T-cell-free system and, importantly, this is
unaffected by the addition of TGF-b itself. Thus, although
exogenous TGF-b is not added during the second phase
of the Treg generation protocol, the population of DC
used to drive the T-cell response in the presence of IFN-g has
the capacity to produce endogenous TGF-b. In order to ask
whether endogenous TGF-b plays a role in the emergence of
Foxp3
1 cells in the IFN-g protocol, CBA CD4
1 cells were
co-cultured with GM-CSF/TGF-b B10 BM DC in the presence of
IFN-g (5ng/mL), without or with neutralizing anti-TGF-b
(10mg/mL), or SB 431542 (10mM), a selective inhibitor of
activin receptor-like kinase 5, the TGF-b type I receptor [40, 41].
Cells were restimulated on day 7, harvested on day 14,
and intracellular Foxp3 expression was analyzed. As shown in
Fig. 5B, the proportion of Foxp3
1 cells decreased from 40.1 to
27.0% when the TGF-b signalling inhibitor SB 431542 was
added, and to 21.2% in the presence of anti-TGF-b antibody. The
absolute number of Foxp3
1 cells also decreased from
61.5710.510
3 in the standard IFN-g conditioning to
13.572.510
3 when SB 431542 was added (means7SD of
two independent experiments). Although neither the inhibitor
nor the antibody totally prevented an increase in the proportion
Eur. J. Immunol. 2008. 38: 2512–2527 Gang Feng et al. 2516
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1 cells, efﬁcacy of this inhibitor concentration was
conﬁrmed by the fact that, when CD4
1 cells were driven by
APC in the presence of exogenous TGF-b alone, an increase in
Foxp3
1 cells was essentially abolished and the proportion
remained virtually the same as in the starting population (Fig.
5B, lower panel). These data support previous reports that TGF-b
signalling is important for the maintenance of Treg [36–39] and
indicate that signalling by endogenous TGF-b also plays a role in
this ex vivo IFN-g-conditioning system. However, the TGF-b
inhibitor data clearly show that the emergence of Foxp3
1 cells in
the IFN-g protocol is the result if several interrelated factors of
which endogenous TGF-b is an important but not predominant
component.
STAT1 signalling is essential for a Treg-dominant
response
CD4
1 T cells and DC both express functional IFN-g receptors
and thus either population could be responding to IFN-g in this ex
vivo conditioning system. Since STAT1 phosphorylation is critical
for IFN-g signalling [42, 43], we took advantage of
IFN-g receptor- (IFNGR KO) and Stat1-deﬁcient (Stat1
/) mice
to determine in which population an IFN-g response
was essential. Naive wild-type 129Sv/Ev (129) or Stat1
/ 129
CD4
1 T cells were co-cultured with GM-CSF/TGF-b BM DC from
either wild-type or IFNGR KO B6 mice. Although 129 and B6 mice
are both H2
b, these strains are mismatched for multiple
minor histocompatibility antigens, demonstrated by the fact
that 129 mice reject B6 skin grafts acutely (MST 16 days) and
B6 APC drive vigorous proliferation of 129 CD4
1 T cells in vitro
as judged by CFSE dilution (64% of cells41 division at day 7,
data not shown). In order to identify the key responders to IFN-g
in this system, combinations were established where both
populations can respond to IFN-g (Fig. 6A, positive control),
neither population can respond to IFN-g (Fig. 6B, negative
control), and where the IFN-g response is restricted to either
T cells or DC (Fig. 6C and D, respectively). Cells were
restimulated on day 7, harvested on day 14, and intracellular
Foxp3 expression was analyzed. As shown in Fig. 6A and C,
the proportions of Foxp3
1 cells were similar when CD4
T cells were driven by IFNGR KO B6 BM DC (32.1%) and when
driven by wild-type B6 BM DC (31.8%), suggesting that a
DC response to IFN-g is not obligatory in this system. However,
when Stat1
/ 129 CD4
1 T cells were co-cultured with DC from
wild-type B6 mice, exogenous IFN-g failed to increase the
proportion of Foxp3
1 cells recovered (8.3 versus 10.1%, with
and without IFN-g, respectively; Fig. 6D). In fact, the proportion
of Foxp3
1 cells was essentially the same as that seen
when neither cell population was capable of responding to
IFN-g (Fig. 6B). Similar results were obtained using wild-type or
Stat1
/ 129 CD4
1 T cells stimulated with GM-CSF/TGF-b BM
DC from CBA (H2
k) mice at each concentration of IFN-g tested
(Fig. 6E and F). Taken together, these results indicate that, in the
IFN-g-conditioning protocol described, T-cell signalling via
STAT1 is essential for the enrichment of Foxp3
1 T cells.
Non-redundant role for STAT1 signalling in Th17 and
Foxp3
1 T-cell development
Cytokine signalling through STAT transcription factors is
essential for T-cell differentiation. For instance, STAT4
and STAT6 are historically linked with Th1 and Th2 develop-
ment, respectively, while more recently STAT3 has been
linked with the development of Th17 cells and STAT5 with
regulatory T cells [44]. We wished to examine the impact
of STAT1 deﬁciency on the emergence of Foxp3
1 and Th17
T cells in the presence of IFN-g, particularly since it has
been shown that Th17 cell development is enhanced in
Figure 3. Expression of IL-6 has a negative impact on IFN-dependent
Treg development. (A) BM cells were cultured in the presence of 2ng/
mL GM-CSF with (GT-DC) or without (G-DC) 2ng/mL TGF-b, harvested
at day 6 and stimulated in the absence of T cells with recombinant
CD40L for 24h to mimic reverse stimulation via CD40-CD40L interac-
tions. IL-6 RT-PCR data are normalized to a housekeeping gene GAPDH,
and are the means7SD of two independent experiments (left panel).
Supernatants were collected for IL-6 ELISA analysis and results
normalized to 410
5 input cells in 2mL medium (right panel). (B)
Puriﬁed naive CBA CD4
1 T cells were co-cultured with wild-type B6
(WT B6) or IL-6 knockout B6 (IL-6 KO B6) GM-CSF/TGF-b-differentiated
BM DC in the presence of IFN-g (5ng/mL). Cells were restimulated on
day 7 under the same conditions, harvested on day 14, and
intracellular Foxp3 expression was analyzed. Numbers in each dot
plot indicate the frequency of cells in the quadrant. Data are
representative of two independent experiments.
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/ mice [45]. In the absence of exogenous cytokines
(neutral conditions), Th17 cell development was enhanced in
Stat1
/ T cells (Fig. 7A versus B, left panels and summary
histogram), consistent with Stat1-dependent regulation of Th17
responses in normal T cells [45], possibly by endogenous IFN-g.
The fact that addition of exogenous IFN-g did not markedly
inhibit Th17 responses suggests that, although the level of
endogenous IFN-g in these cultures is too low to drive the
enrichment of Foxp3
1 Treg (Figs. 1B and D and 7A), it is
sufﬁcient to inﬂuence Th17 cell programming (Fig. 7A, left and
center panels). As with IFN-g, the addition of TGF-b as the only
cytokine increased the proportion of Foxp3
1 cells 5–7-fold in
wild-type cells (Fig. 7A, left versus right panel) but had no effect
in Stat1
/ cells (Fig. 7B, left versus right panels). These data
indicate that STAT1 signalling plays an important role in Treg
generation not only in the IFN-g protocol but also in TGF-b-based
protocols where T cells are driven by allogeneic APC. Indeed,
STAT1 signalling may be a key factor in the balance between
Treg and non-Treg populations in the wider context. In terms of
absolute numbers, we have found that Stat1
/ mice have
essentially normal numbers of Foxp3
1 cells, but these mice
have profound splenomegaly and approximately ten times more
CD4
1 T cells with an activated phenotype (CD25
1 Foxp3
) than
wild-type controls (not shown).
NO mediates the IFN-c-conditioning-related Foxp3-
dominant response
IFN-g and STAT1 signals play an important role in the induction
of NO [46, 47] and real-time PCR analysis revealed a clear
positive correlation between inducible NO synthase (iNOS) and
Figure 4. The ex vivo IFN-g-conditioning protocol extinguishes Th2 and Th17 responses. Upper panel: Puriﬁed naive CBA CD4
1 T cells were co-
cultured with B10 GM-CSF differentiated BM DC (G-DC) without additional cytokines (neutral conditions). Middle panel: Puriﬁed naive CBA CD4
1 T
cells were co-cultured with B10 GM-CSF/TGF-b-differentiated BM DC (GT-DC) under neutral conditions. Lower panel: Puriﬁed naive CBA CD4
1 T
cells were co-cultured with B10 GM-CSF/TGF-b-differentiated BM DC in the presence of IFN-g (5ng/mL). Cells were restimulated under the same
conditions on day 7, harvested on day 14, treated for 4h with PMA and ionomycin, and stained for intracellular IFN-g, IL-4 and IL-17 expression.
Plots are gated on T cells and numbers in the dot plots indicate the frequency of cells in each region. Data are representative of two to three
independent experiments.
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not shown). In order to ask whether NO is directly involved in the
IFN-g-conditioning protocol, naive CBA CD4
1 T cells were co-
cultured with GM-CSF/TGF-b B10 BM DC in the presence of
IFN-g (5ng/mL), with or without N-methyl-L-arginine (L-NMMA)
(0.1–1.0mM), a widely used inhibitor of both constitutive and
inducible forms of NOS [48, 49]. Cells were restimulated on
day 7, harvested on day 14, and intracellular Foxp3 expression
was analyzed. In the absence of L-NMMA, the proportion of
Foxp3
1 cells was 40.076.3%, but NOS inhibition resulted in a
striking dose-dependent decrease: 33.4715.4% with 0.1mM,
18.2714.4% with 0.5mM and 4.572.6% with inhibitor at a ﬁnal
concentration of 1.0mM (po0.05, no inhibitor versus 1mM
inhibitor; Fig. 8A). In addition, the absolute numbers of Foxp3
1
cells recovered also decreased from 30.078.510
3 in the
absence of L-NMMA to 13.572.110
3 in the presence of 1mM
Figure 5. Enrichment of Foxp3
1 cells depends on exogenous IFN-g and endogenous TGF-b. (A) BM cells were cultured in the presence of
2ng/mL GM-CSF with (GT-DC) or without (G-DC) 2ng/mL TGF-b, harvested at day 6 and stimulated in the absence of T cells with recombinant
CD40L for 24h to mimic reverse stimulation by CD40–CD40L interactions. TGF-b RT-PCR data are normalized to the housekeeping gene GAPDH and
are means7SD of two independent experiments (left panel). TGF-b production in supernatants was determined by ELISA and results
were normalized to 410
5 input cells in 2mL medium (right panel). (B) Upper panel: Puriﬁed naive CBA CD4
1 T cells were co-cultured with B10
GM-CSF/TGF-b-differentiated bone marrow DC in the presence of 5ng/mL IFN-g alone, or with IFN-g1SB 431542 (10mM), or anti-TGF-b antibody
(10mg/mL). Lower panel: Puriﬁed naive CBA CD4
1 T cells were co-cultured with B10 GM-CSF/TGF-b-differentiated BM DC in the presence of TGF-b
(2ng/mL), without or with SB 431542 (10mM). Cells were restimulated on day 7 under the same conditions, harvested on day 14, and intracellular
Foxp3 expression was analyzed. Numbers in each dot plot indicate the frequency of cells in the quadrant. Data are representative of two
independent experiments.
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1 cells is mediated via T-cell STAT1 signaling. (A) Puriﬁed naive wild-type (WT) 129 CD4
1 T cells were co-
cultured with wild-type B6 GM-CSF/TGF-b-differentiated BM DC in the absence or presence of IFN-g (5ng/mL). (B) Puriﬁed naive STAT1 knockout (KO) 129
CD4
1 T cells were co-cultured with IFN-g receptor knockout (IFNGR KO) B6 GM-CSF/TGF-b-differentiated BM DC in the absence or presence of IFN-g (5ng/
mL). (C) Puriﬁed naive wild-type (WT) 129 CD4
1 T cells were co-cultured with IFN-g receptor knockout (IFNGR KO) B6 GM-CSF/TGF-b-differentiated BM DC
in the absence or presence of IFN-g (5ng/mL). (D) Puriﬁed naive STAT1 knockout (KO) 129 CD4
1 T cells were co-cultured withw i l d - t y p e( W T )B 6G M - C S F /
TGF-b-differentiated BM DC in the absence or presence of IFN-g (5ng/mL). Cells were restimulated on day 7, harvested on day 14, and intracellular Foxp3
expression was analyzed. Numbers in each dot plot indicate the frequency of cells in the quadrant; data are representative of two to three independent
experiments. (E) Puriﬁed naive wild-type (WT) 129 CD4
1 T cells were co-cultured with GM-CSF/TGF-b-differentiated CBA BM DC in the absence or presence
of IFN-g (0.5–50ng/mL). (F) Puriﬁed naive STAT1 knockout (KO) 129 CD4
1 T cells were co-cultured with GM-CSF/TGF-b-differentiated CBA BM DC in the
absence or presence of IFN-g (0.5–50ng/mL). Cells were restimulated on day 7, harvested on day 14, and intracellular Foxp3 expression was analyzed.
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role in the development of Foxp3
1 Treg driven by IFN-g
conditioning.
We then asked whether a non-cellular source of NO could
substitute for exogenous IFN-g in the ex vivo conditioning
protocol. Naive CBA CD4
1 T cells were co-cultured with
GM-CSF/TGF-b B10 BM DC in the absence of exogenous IFN-g
but with or without S-nitroso-N-acetyl-penicillamine (SNAP),
a NO donor widely tested ex vivo [48, 50, 51]. Cells were resti-
mulated on day 7 under the same conditions, harvested on
day 14, and intracellular Foxp3 expression was analyzed.
As shown in Fig. 8B, the proportion of Foxp3
1 cells increased in a
concentration-dependent manner from 0.1 to 0.4mM SNAP in
that the proportion of Foxp3
1 cells was 22.1716.9, 33.0724,
49.5714.9 and 67.9715.4% at 0.1, 0.2, 0.3 and 0.4mM SNAP,
respectively. Most striking is that the absolute number of Foxp3
1
cells showed a clear concentration-dependent increase.
The number of Foxp3
1cells recovered was 25.072.810
3,
35.572.110
3 and 52.5716.310
3 at SNAP concentrations of
0.1, 0.2 and 0.3mM, respectively. The yield decreased dramati-
cally when SNAP was used at higher concentrations
(0.4–0.5mM), identifying a concentration of 0.3mM as the
optimal dose in this ex vivo system. Collectively, these data
demonstrate that induced NO is an indispensable soluble factor
Figure 7. Non-redundant role for STAT1 signalling in the reciprocal development of regulatory and Th17 cells ex vivo. Puriﬁed naive CD4
1 T cells
from wild-type 129 mice (A) or STAT1 knockout 129 mice (B) were co-cultured with B6 GM-CSF/TGF-b-differentiated BM DC in the absence or
presence of IFN-g (5ng/mL), or TGF-b (2ng/mL). Cells were restimulated under the same conditions on day 7, harvested on day 14, treated for 4h
with PMA and ionomycin, and analyzed for intracellular Foxp3 and IL-17 expression in gated (TCR-b
1) T cells. Figures in representative dot plots
indicate the frequency of cells in each quadrant and summary histograms show means and SD of three independent experiments.
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1 cells driven by alloantigen
in the IFN-g-conditioning protocol. Interestingly, at optimal
concentrations of either exogenous IFN-g or NO donor, the
proportion of Foxp3
1 cells was similar, but the provision of NO
increased the yield of both total cells and Treg. This is partly
explained by the fact that, as judged by annexin V staining, the
level of cell death seen in the presence of the optimal concen-
tration of NO donor (0.3mM) is substantially lower than that
seen in the presence of the optimal concentration of IFN-g
(7.974.0 and 16.678.0% for 1SNAP and 1IFN-g, respectively;
Figure 8. IFN-g-conditioning results in NO-mediated Foxp3 upregulation. (A) Puriﬁed naive CBA CD4
1 T cells were co-cultured with GM-CSF/TGF-
b-differentiated B10 BM DC15ng/mL IFN-g in the absence or presence of the NOS inhibitor L-NMMA (0.1–1.0mM). Cells were restimulated on day 7,
harvested on day 14 and stained for TCR-b and intracellular Foxp3 expression. (B) Puriﬁed naive CBA CD4
1 T cells were co-cultured with GM-CSF/
TGF-b-differentiated B10 BM DC in the absence or presence of the NO donor SNAP (0.1–0.3mM). No exogenous IFN-g was added. Cells were
restimulated on day 7, harvested on day 14 and stained for TCR-b and intracellular Foxp3 expression. Figures in representative dot plots indicate
the frequency of Foxp3
1 cells and histograms show means and SD of three independent experiments.
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this system reduces the overall size of the responding T-cell pool
due to its anti-proliferative and pro-apoptotic effects (Fig. 2 and
[23–25, 27, 28]). Indeed, an overall reduction in the size of the
responding T-cell population may be an important prerequisite
for regulation [52, 53].
Discussion
Treg cells generated or expanded ex vivo have signiﬁcant
potential as cellular therapeutics [54]. Several such ex vivo
protocols exist [37, 38, 55] and understanding the underlying
mechanisms responsible for Treg generation will have an
important inﬂuence in optimizing and identifying the most
suitable protocols for clinical evaluation. In the current study,
we have demonstrated that stimulation of mouse CD4
1 T cells by
allogeneic GM-CSF/TGF-b-conditioned immature DC in the
presence of exogenous IFN-g leads to a T-cell response dominated
by the emergence of Foxp3
1 regulatory T cells. Signiﬁcantly, the
resulting population can regulate rejection responses in vivo
without further manipulation. Our working hypothesis at present
is that regulation is mediated by Foxp3
1 cells contained within
the resulting population, but we cannot formally rule out a
contribution by other regulatory populations such as IL-10-
producing Tr1-like cells. However, as judged by intracellular
cytokine staining, we have been unable to detect IL-10 production
by IFN-g-conditioned cells, and preliminary experiments conducted
using other donor–recipient combinations have revealed a positive
correlation between the degree of Foxp3 enrichment and regula-
tion in vivo. We are currently conducting experiments in which
sorted GFP
–Foxp3
– cells will be used as the input population and
resultant GFP
1Foxp3
1 and GFP
–Foxp3
– cells will be assessed
independently for functional regulatory capacity. We hope that this
will allow us to determine deﬁnitively whether or not regulation is
conﬁned to alloantigen-driven Foxp3
1 T cells.
The addition of exogenous IFN-g appears to result
in an overall selection for cells with a Treg phenotype via
proliferation, conversion of non-Treg precursors and induction of
cell death within the responding non-Treg population, but we
have found little evidence for an increase in the absolute size of
the Foxp3
1 population compared with that recovered under
identical conditions in the absence of IFN-g. Despite this, the
resulting cells regulate rejection in an alloantigen-speciﬁc manner
and we speculate that alloantigen stimulation by GM-CSF/TGF-b
BM DC in the presence of IFN-g drives an overall shift in the
speciﬁcity of Foxp3
1 cells, resulting in a relatively oligoclonal
population in much the same way as repeated in vitro stimulation
selects for the survival of responding non-regulatory T cells in
other settings. We are currently attempting to test this hypothesis
by seeding TCR-transgenic T cells into polyclonal populations
followed by alloantigen challenge in the presence of IFN-g.
When total CD4
1 T cells are used as the input population,
there is clear evidence of preferential apoptosis or necrosis within
non-Treg responders (Fig. 2D). The fact that IFN-g can enhance
apoptosis within activated T-cell populations has been known for
many years [23–25], but the reasons why Treg appear to be less
sensitive to IFN-g-mediated cell death in this system are not
known at present. One possibility is suggested by the fact that, in
terms of class II and costimulatory molecule expression, BM DC
conditioned with GM-CSF1TGF-b are much more heterogeneous
than their classically derived counterparts and thus probably
drive a similarly heterogeneous T-cell response resulting in fully
activated Foxp3
– effector cells and those that have defaulted to
express Foxp3
1 because of suboptimal activation. The idea that
suboptimal stimulation of responding T cells is a prerequisite for
Treg generation in this system (as has been reported in the
induction of Treg in vivo [56]) is supported by the fact that, in our
hands, IFN-g failed to promote the conversion of Foxp3
–/GFP
–
CD4 cells to Foxp3/GFP
1 cells driven by anti-CD3mAb, a
stimulus expected to provide supra-optimal T-cell activation
(data not shown). Indeed, it was on this basis that GM-CSF/TGF-
b-conditioned BM-derived DC were chosen as the preferred APC
population in the IFN-g-conditioning protocol because this
pretreatment arrests DC maturation and retards MHC and costi-
mulatory molecule upregulation. While we have not formally
tested whether other isolated APC populations can also drive the
selection of Foxp3
1 Treg in the IFN-g protocol, previous attempts
using T-cell-depleted spleen cells as APC gave extremely unpre-
dictable results. However, it seems likely that other immature
APC would be capable of inducing the generation of Treg in this
system, particularly if they retained the capacity for production of
TGF-b (Fig. 5). It would be expected that suboptimally activated
T cells would be less susceptible to AICD and, indeed, we have
found, using CFSE-based assays, a clear correlation between
T-cell proliferation and death in the IFN-g conditioning protocol
(data not shown). Furthermore, the fact that Treg tend
to be anergic might also confer a relative resistance to AICD.
An additional possibility is that alloantigen-driven Treg have an
increased expression of anti-apoptotic molecules such as Bcl-xL,a s
has recently been reported in naturally occurring Foxp3
1 Treg
[57]. We are currently investigating the expression of anti-
apoptotic genes and IFN-g receptors in Foxp3
– and Foxp3
1 cells
as a function of time in the IFN-g-conditioning protocol.
Under neutral conditions, CD4
1 T cells driven by allogeneic
GM-CSF/TGF-b-differentiated DC tend to have an intrinsic bias
toward Th2 and Th17 responses because these APC produce
signiﬁcant amounts of both TGF-b and IL-6. Signiﬁcantly, this
bias is prevented by the addition of exogenous IFN-g without
resulting in an overt Th1 response (Fig. 4), an observation
entirely consistent with previous studies [58–60]. Again, these
data suggest that IFN-g selectively inhibits development of the
effector T-cell population while maintaining the development of
Treg. Thus, the effect of exogenous IFN-g in this system is to
inﬂuence the development of a dominant Treg response by
inducing death within Foxp3
– responders and by skewing the
overall T-cell response away from Th2 and Th17 cells. In this
context, it is interesting to note that, in a rather different ex vivo
system where the emergence of Foxp3
1 T cells is dependent on
exogenous TGF-b [61], IL-4 appears to be more antagonistic than
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current study where one of the effects of exogenous IFN-g is to
inhibit Th2 development (Fig. 4).
Our data show that NO is critically involved in the ex vivo IFN-
g-conditioning protocol. IFN-g is an efﬁcient inducer of NOS
activity [46], an observation consistent with the described effects
of NO, an important effector molecule in immunity, particularly
against intracellular pathogens. However, data are emerging
indicating that NO also plays a regulatory role in immune
responses [62]. For example, iNOS-mutant mice develop signiﬁ-
cantly more pronounced Th1 responses than wild-type mice upon
infection, and IFN-g-induced NO can downregulate Bcl-2
expression and induce apoptosis of primed T cells [63, 64].
Williams et al. have shown that T cells can produce NO upon TCR
signalling and that this is closely involved in AICD [65]. In
addition, NO can induce upregulation of IFN-g receptor 2
expression on T cells, and these T cells are thus susceptible to
IFN-g [66]. IFN-g receptor signalling with subsequent STAT1
phosphorylation is critical for the function of IFN-g [42, 43].
Stat1
/ mice develop EAE and show enhanced generation of
Th1 cells, suggesting that STAT1 signalling is not only non-obli-
gatory for Th1 development but may play a negative feedback
role on effector cell responses [67, 68]. A potential explanation
for such observations has recently been provided by studies
demonstrating that Stat1
/ mice have enhanced Th17 responses
[45], indicating that STAT1 signalling plays a critical negative
role in Th17 cell differentiation. Indeed, both IFN-g and IL-27
have been shown capable of suppressing Th17 development via
signalling through STAT1 [69] and a recent report has demon-
strated that STAT1 phosphorylation can lead to the transcription
of iNOS [47]. Our data demonstrate that NO can play an
important role as a downstream mediator of this effect since
inhibition of NOS completely abrogated IFN-g conditioning and
provision of an NO donor in the absence of exogenous IFN-g also
resulted in a Foxp3
1 Treg-dominant response.
The data presented in this study provide novel insights into
the means and mechanism by which a dominant alloreactive
regulatory T-cell population can be encouraged to develop ex
vivo. The fact that the protocol results in partial selection of
regulatory cells by shifting the balance between Treg and non-
Treg populations suggests that, if used in concert, the IFN-g
protocol followed by polyclonal expansion might provide sufﬁ-
cient numbers of enriched regulatory cells for therapeutic use.
Indeed, in this regard the preferential elimination of alloreactive
non-Treg cells might confer a signiﬁcant beneﬁt. Recently, two
other independent studies have demonstrated that exogenous
IFN-g can be used to inﬂuence Treg development ex vivo. In the
ﬁrst, Wang et al. demonstrated that polyclonal activation of
mouse CD4
1CD25
 T cells with anti-CD3 antibody in the
presence of IFN-g resulted in a population of CD25
1 T cells that
inhibited the development of EAE almost as effectively as natu-
rally occurring Treg [70]. In the second study, Brem-Exner et al.
showed that exposure of lymph node cells in vitro to IFN-g-
conditioned monocytes led to an expansion of CD25
1Foxp3
1
T cells, and while the ability of these ex vivo generated/expanded
cells to regulate responses in vivo was not formally tested, the fact
that adoptive transfer of the IFN-g-conditioned monocyte popu-
lation led to a resolution of colitis in a mouse model of inﬂam-
matory bowel disease is consistent with an in vivo conversion
driven by this APC population [8].
The results of the current study extend these observations
signiﬁcantly by demonstrating that IFN-g can be used to shape
the ex vivo T-cell response to alloantigens away from effector cell
differentiation in favor of Treg development and that without
further manipulation the resultant population can control acute
allograft rejection. Although such approaches have potential
therapeutic use in both transplantation and autoimmune disease,
we believe that transplantation offers the unique advantage that
APC from the graft donor can be used to drive Treg selection.
Such antigen-speciﬁc activation is unlikely to be possible in
autoimmunity, except in those cases where the antigens are well
deﬁned. Although living donor transplantation offers the most
immediate possibility for donor-reactive Treg generation, the
observation that some immunosuppressive agents are permissive
and may select for regulatory T cells [55] suggests the possibility
of combining Treg generation with short-course immunosup-
pression, to extend this type of approach to deceased donor
transplantation.
Materials and methods
Mice
CBA.Ca (CBA, H2
k), C57BL/10 (B10, H2
b), C57BL/6 (B6, H2
b),
129Sv/Ev (129, H2
bc), CBA-recombination-activating gene 1 knock-
out (CBA-Rag
/,H 2
k; kindly provided by Dr. D. Kioussis, Division of
Molecular Immunology, National Institute for Medical Research, Mill
Hill, London), IFN-g receptor knockout B6 mice (IFNGR KO, H2
b;
kindly provided by Prof. Siamon Gordon, Sir William Dunn School of
Pathology, Oxford, UK), and IL-6 knockout mice were obtained from
a n dh o u s e di nt h eB i o m e d i c a lS e r v i c es Unit, John Radcliffe Hospital.
Stat1
/ 129 mice were purchased from Taconic Farm (Hudson,
NY). Foxp3gfp knock-in (Foxp3gfp.KI) B6 mice and DBA/2 mice were
bred and housed in the Transplant Research Center, Beth Israel
Deaconess Medical Center, Harvard Medical School (Boston, MA)
[33]. Sex-matched mice between 6 and 12wk of age at the time of
ﬁrst experimental procedure were used in all experiments.
Reagents and mAb
The hybridomas TIB120 (anti-MHC class II) and RA3.6B2 (anti-
B220) were obtained from the American Type Culture Collection;
YTS169 (anti-CD8) and YTA3.1 (anti-CD4) [71] were kindly
provided by Prof. H. Waldmann (Sir William Dunn School of
Pathology, Oxford, UK). RM4-5-PerCP, 11B11-PE, XMG1.2-FITC
and JES-19F1-PE were purchased from BD Pharmingen. The anti-
Foxp3 antibody FJK-16s was obtained from eBioscience and used
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were purchased from Sigma-Aldrich.
Cell puriﬁcation
CD4
1 T cells and CD25
CD4
1 T cells were isolated using CD4 or
CD25 MicroBeads (Miltenyi). Foxp3
– GFP
– CD4 T cells were ﬂow-
sorted (BD-Biosciences FACS-Vantage). On reanalysis, all popu-
lations were 95–99% pure.
In vitro generation of BM DC
BM DC were generated from donor mice according to published
methods [35, 72]. DC precursor-enriched BM cells were cultured with
2ng/mL each of rmGM-CSF and rhTGF-b1 (PeproTech, London,
UK). At day 6, DC were harvested, washed and counted prior to use.
IFN-c-conditioning protocol
Cell culture used RPMI 1640 containing 10% FCS, 2mM
L-glutamine, 0.5mM 2-mercaptoethanol (Sigma) and 100U/mL of
penicillin and streptomycin (Sigma). Puriﬁed naive CD4
1
Tc e l l s( 5 10
5 were co-cultured with 510
4 allogeneic BM DC/
2mL well in RPMI 1640 medium containing 10% FCS in
24-well plates (Corning, NY), in the presence of 5ng/mL exogenous
rmIFN-g (PeproTech). On day 7, half of the medium was replaced
with fresh medium containing the same concentration of recombi-
nant IFN-g and the same number of DC. After two rounds of
stimulation, cells were harvested for phenotypic analysis, or for
functional evaluation in an adoptive transfer model.
Adoptive transfer and skin transplantation
CBA-Rag
/ mice were reconstituted intravenously with 110
5
CD25
CD4
1 cells from naive CBA with or without 210
5 ex vivo
conditioned cells. The following day, full-thickness B10 tail skin
allografts were transplanted onto graft beds prepared on the left
ﬂank.
Statistical analysis
Graft survival between transplant groups was compared using
Kaplan–Meier survival curves and the Log-rank test (GraphPad
Prism) with signiﬁcance at po0.05. Two-tailed comparisons were
made using the Mann–Whitney test.
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